Summary

The global Pregnancy and Ovulation Testing market is projected to grow from US$ 689 million in 2025 to US$ 970 million by 2032, at a CAGR of 5.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Pregnancy and Ovulation Testing refers to in-vitro diagnostic products used to identify pregnancy and evaluate the fertile window through the detection of reproductive hormones. Pregnancy testing is primarily based on human chorionic gonadotropin, particularly qualitative hCG detection in urine for home self-testing and point-of-care use, while professional products may also support serum testing. Ovulation testing primarily identifies the urinary luteinizing hormone surge preceding ovulation, with advanced systems extending monitoring to multiple fertility hormones such as estrogen metabolites alongside LH. The product scope covers visual line-read tests, digital display tests and smartphone- or reader-assisted systems, delivered in strip/dipstick, cassette, midstream and reader-based formats. The research focuses on Pregnancy and Ovulation Testing products used for home self-testing, hospitals and clinics, fertility centers and diagnostic laboratories, reflecting both consumer self-diagnosis and professional reproductive-health testing applications.
Key Findings
Pregnancy testing remains centered on urine hCG rapid detection products
Ovulation testing is primarily built around urinary LH surge detection
Visual line tests remain a foundational conventional product format
Digital and reader-assisted formats reduce ambiguity in result interpretation
Multi-hormone testing extends ovulation assessment beyond single-LH detection
Home self-testing is the core consumer application scenario
Market Trends
Pregnancy and Ovulation Testing is shifting from simple qualitative line interpretation toward earlier detection, clearer digital outputs, individualized hormone assessment and connected fertility management. Conventional lateral-flow products retain their importance because of low complexity, portability and broad channel suitability, but premium product development increasingly focuses on reducing interpretation uncertainty and providing more actionable information. Digital ovulation systems can automatically interpret test results, while more advanced products monitor both LH and estrogen-related biomarkers to identify a broader fertile window rather than relying solely on a fixed LH threshold. Smartphone-assisted readers and reusable digital devices are further extending the category from a single test result toward cycle tracking and longitudinal hormone-pattern management. In pregnancy testing, product innovation is concentrated on lower detection thresholds, earlier testing windows, clearer result presentation and digital formats. The continued appearance of digital and early-detection pregnancy tests in regulatory databases also demonstrates that product differentiation is increasingly occurring around user experience, sensitivity and interpretation rather than around the underlying hCG biomarker itself.
Market Dynamics
Drivers
Demand is supported by the combination of reproductive-health awareness, preference for private and convenient testing, and the ability of urine-based rapid tests to provide results without laboratory infrastructure. Pregnancy testing addresses a recurring and time-sensitive diagnostic need, while ovulation testing supports consumers actively planning conception and seeking more precise identification of fertile days. The relatively simple workflow of strips and midstream devices supports wide availability through pharmacies and consumer channels, while professional hCG products remain relevant in hospitals, clinics and laboratories. The increasing integration of fertility testing with digital interpretation and cycle-management tools is also widening the functional value of the category beyond a single qualitative result.
Restraints
The primary limitation is that biological variability and testing timing directly affect result reliability in real-world use. Pregnancy tests may produce false-negative results when used too early because urinary hCG has not yet reached the detection threshold, while improper sampling or interpretation can further reduce effective accuracy. Ovulation testing faces a different limitation: an LH surge predicts impending ovulation but does not itself confirm that ovulation has occurred, and individual hormone patterns, irregular cycles, medical conditions and certain fertility medications can complicate result interpretation. These limitations mean that improvements in analytical sensitivity alone cannot completely eliminate user-related and physiological uncertainty.
Opportunities
The clearest product opportunity lies in moving from single-marker qualitative testing toward integrated fertility intelligence. Digital readers, reusable devices, smartphone-assisted interpretation and multi-hormone testing can create a more differentiated proposition than conventional single-use visual strips. Dual-hormone systems that combine LH with estrogen-related biomarkers can identify a broader fertility window, while newer platforms are exploring additional reproductive hormones and longitudinal pattern analysis. At the same time, conventional low-cost tests retain substantial opportunities in markets where pharmacy penetration, e-commerce availability and consumer awareness are still developing. This creates room for parallel growth of value-oriented visual tests and premium digital fertility-management products rather than a complete substitution of one format by another.
Challenges
Competition increasingly operates across several dimensions simultaneously: analytical performance, manufacturing consistency, regulatory compliance, brand trust, retail access, digital user experience and price. Conventional pregnancy and ovulation strips have relatively standardized core immunochromatographic technology, making product differentiation difficult when suppliers compete primarily on sensitivity specifications and cost. At the premium end, digital and multi-hormone systems require stronger algorithm development, device reliability, user-interface design and consumer education. Manufacturers must also manage differences in product classification, labeling, self-test regulation and distribution requirements across markets. As a result, scaling globally requires not only manufacturing capability but also sustained regulatory, channel and brand investment.
Industry Chain Analysis
The Pregnancy and Ovulation Testing industry chain begins with biological reagents and diagnostic materials, including hormone-specific antibodies, membrane materials, sample and absorbent pads, signal-generating materials such as colloidal gold, plastic components and packaging. Digital and reader-based products add electronic components, optical or signal-reading modules, displays, batteries, connectivity components and software algorithms. Midstream manufacturers undertake reagent formulation and coating, membrane assembly, strip cutting, housing assembly, calibration, quality control, packaging and regulatory documentation. The established use of colloidal-gold platforms for hCG and LH rapid tests illustrates the continued importance of mature lateral-flow manufacturing infrastructure, while digital products add a separate electronics and software layer to the value chain. Downstream routes differ by positioning. Consumer-oriented products move primarily through pharmacy, mass retail and online channels, whereas professional products are supplied to hospitals, clinics, fertility centers and diagnostic laboratories. Value creation is therefore increasingly bifurcated: conventional visual tests compete through scalable manufacturing, consistent quality and channel efficiency, while premium products rely more heavily on brand recognition, simplified interpretation, multi-hormone capability and digital functionality.
Segment Insights
By testing purpose, Pregnancy Tests and Ovulation Tests address distinct but closely connected reproductive-health needs. Pregnancy testing is centered on hCG detection and spans both consumer urine testing and professional urine or serum testing. Professional rapid hCG assays are available in cassette and dipstick formats for point-of-care environments, while consumer products emphasize midstream convenience and clear result interpretation. Ovulation testing is primarily based on urinary LH detection and generally involves repeated testing over several days within a menstrual cycle, supporting multi-test packages and reusable-reader models. The segment is also becoming technologically broader as dual-hormone systems use LH together with estrogen-related signals to identify high- and peak-fertility periods.
By result-reading method and physical form, visual line-read products constitute the conventional foundation of the market, spanning test strips, cassettes and midstream devices. Their competitive advantages are simplicity, low hardware requirements and suitability for both branded retail products and large-scale manufacturing. Digital display and reader-assisted products occupy a more differentiated position by automatically interpreting test signals and reducing ambiguity associated with comparing line intensity. Smartphone-assisted systems extend this approach further by storing results and tracking hormone or cycle patterns. Consequently, technological segmentation is increasingly moving from a simple distinction between test formats toward a broader separation between single-result diagnostic products and connected fertility-monitoring systems.
Downstream Market Opportunities
Home self-testing represents the central consumer-facing opportunity because pregnancy and ovulation testing both benefit from privacy, immediate access and simple urine-based workflows. Pharmacies and online retail enable broad distribution of conventional and premium formats, while digital fertility products create additional opportunities among consumers seeking more structured conception planning. Professional demand remains differentiated: hospitals and clinics use rapid pregnancy testing as part of routine clinical decision-making, diagnostic laboratories may use urine or serum hCG tests, and fertility centers have demand for ovulation and reproductive-hormone assessment. QuidelOrtho's professional hCG products, for example, support both urine and serum specimens, demonstrating that the category extends beyond the consumer self-test channel.
Regional Insights
North America represents a highly developed regulatory and commercial environment for Pregnancy and Ovulation Testing, with a broad range of over-the-counter and waived urine hCG products, including traditional visual and digital pregnancy tests. The FDA database continues to record new early-detection and digital products, indicating an active replacement and product-differentiation cycle rather than a static commodity market. Europe also supports a mature self-testing model through pharmacy and consumer diagnostic channels, with manufacturers such as BIOSYNEX offering both pregnancy and ovulation self-tests alongside professional rapid diagnostics.
Asia-Pacific has a structurally different opportunity profile. China hosts multiple manufacturers with broad hCG and LH rapid-test portfolios across strip, cassette and midstream formats, supporting both domestic supply and international manufacturing, while Japan maintains established consumer ovulation-testing products through pharmacy-regulated channels. South Korea also provides examples of digital and smartphone-connected fertility testing. The region therefore combines cost-efficient rapid-test manufacturing with growing capability in higher-value digital fertility products. Market opportunities differ significantly by country according to regulation, pharmacy access, fertility awareness, digital-health adoption and consumer purchasing power, making localization of product positioning and channel strategy particularly important.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Pregnancy and Ovulation Testing market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
SPD (Clearblue)
First Response
Gregory Pharmaceutical (e.p.t)
Equinox Biotech
Wondfo
Easy@Home
BlueCross
Fairhaven Health
PRIMA Lab
Cyclotest
Rohto
Lobeck Medical
QuidelOrtho
Mankind Consumer Products
Hangzhou Singclean Medical
Segment by Type
Coloration Test
Digital Test
Segment by Purpose of Testing
Pregnancy Test
Ovulation Test
Segment by Biomarker
hCG-Based Test
LH-Based Test
Multi-Hormone Test
Segment by Application
Fertility Centers
Hospitals
Clinics
Others
Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Pregnancy and Ovulation Testing study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Pregnancy and Ovulation Testing: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Pregnancy and Ovulation Testing Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Coloration Test
1.2.3 Digital Test
1.3 Market Segmentation by Purpose of Testing
1.3.1 Global Pregnancy and Ovulation Testing Market Size by Purpose of Testing, 2021 vs 2025 vs 2032
1.3.2 Pregnancy Test
1.3.3 Ovulation Test
1.4 Market Segmentation by Biomarker
1.4.1 Global Pregnancy and Ovulation Testing Market Size by Biomarker, 2021 vs 2025 vs 2032
1.4.2 hCG-Based Test
1.4.3 LH-Based Test
1.4.4 Multi-Hormone Test
1.5 Market Segmentation by Application
1.5.1 Global Pregnancy and Ovulation Testing Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Fertility Centers
1.5.3 Hospitals
1.5.4 Clinics
1.5.5 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Pregnancy and Ovulation Testing Revenue Estimates and Forecasts (2021-2032)
2.2 Global Pregnancy and Ovulation Testing Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Pregnancy and Ovulation Testing Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Pregnancy and Ovulation Testing Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Coloration Test: Market Share by Key Players
3.3.2 Digital Test: Market Share by Key Players
3.4 Global Pregnancy and Ovulation Testing Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Pregnancy and Ovulation Testing Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Pregnancy and Ovulation Testing Market by Purpose of Testing
4.2.1 Global Revenue by Purpose of Testing (2021-2032)
4.2.2 Global Revenue-Based Market Share by Purpose of Testing (2021-2032)
4.3 Global Pregnancy and Ovulation Testing Market by Biomarker
4.3.1 Global Revenue by Biomarker (2021-2032)
4.3.2 Global Revenue-Based Market Share by Biomarker (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Pregnancy and Ovulation Testing Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Pregnancy and Ovulation Testing Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Pregnancy and Ovulation Testing Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Pregnancy and Ovulation Testing Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Pregnancy and Ovulation Testing Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Pregnancy and Ovulation Testing Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Pregnancy and Ovulation Testing Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Pregnancy and Ovulation Testing Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Pregnancy and Ovulation Testing Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Pregnancy and Ovulation Testing Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Pregnancy and Ovulation Testing Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 SPD (Clearblue)
11.1.1 SPD (Clearblue) Corporation Information
11.1.2 SPD (Clearblue) Business Overview
11.1.3 SPD (Clearblue) Pregnancy and Ovulation Testing Product Features and Attributes
11.1.4 SPD (Clearblue) Pregnancy and Ovulation Testing Revenue and Gross Margin (2021-2026)
11.1.5 SPD (Clearblue) Pregnancy and Ovulation Testing Revenue by Product in 2025
11.1.6 SPD (Clearblue) Pregnancy and Ovulation Testing Revenue by Application in 2025
11.1.7 SPD (Clearblue) Pregnancy and Ovulation Testing Revenue by Geographic Area in 2025
11.1.8 SPD (Clearblue) Pregnancy and Ovulation Testing SWOT Analysis
11.1.9 SPD (Clearblue) Recent Developments
11.2 First Response
11.2.1 First Response Corporation Information
11.2.2 First Response Business Overview
11.2.3 First Response Pregnancy and Ovulation Testing Product Features and Attributes
11.2.4 First Response Pregnancy and Ovulation Testing Revenue and Gross Margin (2021-2026)
11.2.5 First Response Pregnancy and Ovulation Testing Revenue by Product in 2025
11.2.6 First Response Pregnancy and Ovulation Testing Revenue by Application in 2025
11.2.7 First Response Pregnancy and Ovulation Testing Revenue by Geographic Area in 2025
11.2.8 First Response Pregnancy and Ovulation Testing SWOT Analysis
11.2.9 First Response Recent Developments
11.3 Gregory Pharmaceutical (e.p.t)
11.3.1 Gregory Pharmaceutical (e.p.t) Corporation Information
11.3.2 Gregory Pharmaceutical (e.p.t) Business Overview
11.3.3 Gregory Pharmaceutical (e.p.t) Pregnancy and Ovulation Testing Product Features and Attributes
11.3.4 Gregory Pharmaceutical (e.p.t) Pregnancy and Ovulation Testing Revenue and Gross Margin (2021-2026)
11.3.5 Gregory Pharmaceutical (e.p.t) Pregnancy and Ovulation Testing Revenue by Product in 2025
11.3.6 Gregory Pharmaceutical (e.p.t) Pregnancy and Ovulation Testing Revenue by Application in 2025
11.3.7 Gregory Pharmaceutical (e.p.t) Pregnancy and Ovulation Testing Revenue by Geographic Area in 2025
11.3.8 Gregory Pharmaceutical (e.p.t) Pregnancy and Ovulation Testing SWOT Analysis
11.3.9 Gregory Pharmaceutical (e.p.t) Recent Developments
11.4 Equinox Biotech
11.4.1 Equinox Biotech Corporation Information
11.4.2 Equinox Biotech Business Overview
11.4.3 Equinox Biotech Pregnancy and Ovulation Testing Product Features and Attributes
11.4.4 Equinox Biotech Pregnancy and Ovulation Testing Revenue and Gross Margin (2021-2026)
11.4.5 Equinox Biotech Pregnancy and Ovulation Testing Revenue by Product in 2025
11.4.6 Equinox Biotech Pregnancy and Ovulation Testing Revenue by Application in 2025
11.4.7 Equinox Biotech Pregnancy and Ovulation Testing Revenue by Geographic Area in 2025
11.4.8 Equinox Biotech Pregnancy and Ovulation Testing SWOT Analysis
11.4.9 Equinox Biotech Recent Developments
11.5 Wondfo
11.5.1 Wondfo Corporation Information
11.5.2 Wondfo Business Overview
11.5.3 Wondfo Pregnancy and Ovulation Testing Product Features and Attributes
11.5.4 Wondfo Pregnancy and Ovulation Testing Revenue and Gross Margin (2021-2026)
11.5.5 Wondfo Pregnancy and Ovulation Testing Revenue by Product in 2025
11.5.6 Wondfo Pregnancy and Ovulation Testing Revenue by Application in 2025
11.5.7 Wondfo Pregnancy and Ovulation Testing Revenue by Geographic Area in 2025
11.5.8 Wondfo Pregnancy and Ovulation Testing SWOT Analysis
11.5.9 Wondfo Recent Developments
11.6 Easy@Home
11.6.1 Easy@Home Corporation Information
11.6.2 Easy@Home Business Overview
11.6.3 Easy@Home Pregnancy and Ovulation Testing Product Features and Attributes
11.6.4 Easy@Home Pregnancy and Ovulation Testing Revenue and Gross Margin (2021-2026)
11.6.5 Easy@Home Recent Developments
11.7 BlueCross
11.7.1 BlueCross Corporation Information
11.7.2 BlueCross Business Overview
11.7.3 BlueCross Pregnancy and Ovulation Testing Product Features and Attributes
11.7.4 BlueCross Pregnancy and Ovulation Testing Revenue and Gross Margin (2021-2026)
11.7.5 BlueCross Recent Developments
11.8 Fairhaven Health
11.8.1 Fairhaven Health Corporation Information
11.8.2 Fairhaven Health Business Overview
11.8.3 Fairhaven Health Pregnancy and Ovulation Testing Product Features and Attributes
11.8.4 Fairhaven Health Pregnancy and Ovulation Testing Revenue and Gross Margin (2021-2026)
11.8.5 Fairhaven Health Recent Developments
11.9 PRIMA Lab
11.9.1 PRIMA Lab Corporation Information
11.9.2 PRIMA Lab Business Overview
11.9.3 PRIMA Lab Pregnancy and Ovulation Testing Product Features and Attributes
11.9.4 PRIMA Lab Pregnancy and Ovulation Testing Revenue and Gross Margin (2021-2026)
11.9.5 PRIMA Lab Recent Developments
11.10 Cyclotest
11.10.1 Cyclotest Corporation Information
11.10.2 Cyclotest Business Overview
11.10.3 Cyclotest Pregnancy and Ovulation Testing Product Features and Attributes
11.10.4 Cyclotest Pregnancy and Ovulation Testing Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Rohto
11.11.1 Rohto Corporation Information
11.11.2 Rohto Business Overview
11.11.3 Rohto Pregnancy and Ovulation Testing Product Features and Attributes
11.11.4 Rohto Pregnancy and Ovulation Testing Revenue and Gross Margin (2021-2026)
11.11.5 Rohto Recent Developments
11.12 Lobeck Medical
11.12.1 Lobeck Medical Corporation Information
11.12.2 Lobeck Medical Business Overview
11.12.3 Lobeck Medical Pregnancy and Ovulation Testing Product Features and Attributes
11.12.4 Lobeck Medical Pregnancy and Ovulation Testing Revenue and Gross Margin (2021-2026)
11.12.5 Lobeck Medical Recent Developments
11.13 QuidelOrtho
11.13.1 QuidelOrtho Corporation Information
11.13.2 QuidelOrtho Business Overview
11.13.3 QuidelOrtho Pregnancy and Ovulation Testing Product Features and Attributes
11.13.4 QuidelOrtho Pregnancy and Ovulation Testing Revenue and Gross Margin (2021-2026)
11.13.5 QuidelOrtho Recent Developments
11.14 Mankind Consumer Products
11.14.1 Mankind Consumer Products Corporation Information
11.14.2 Mankind Consumer Products Business Overview
11.14.3 Mankind Consumer Products Pregnancy and Ovulation Testing Product Features and Attributes
11.14.4 Mankind Consumer Products Pregnancy and Ovulation Testing Revenue and Gross Margin (2021-2026)
11.14.5 Mankind Consumer Products Recent Developments
11.15 Hangzhou Singclean Medical
11.15.1 Hangzhou Singclean Medical Corporation Information
11.15.2 Hangzhou Singclean Medical Business Overview
11.15.3 Hangzhou Singclean Medical Pregnancy and Ovulation Testing Product Features and Attributes
11.15.4 Hangzhou Singclean Medical Pregnancy and Ovulation Testing Revenue and Gross Margin (2021-2026)
11.15.5 Hangzhou Singclean Medical Recent Developments

12 Pregnancy and Ovulation Testing Value Chain and Ecosystem Analysis
12.1 Pregnancy and Ovulation Testing Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Pregnancy and Ovulation Testing Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Pregnancy and Ovulation Testing Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Pregnancy and Ovulation Testing Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Pregnancy and Ovulation Testing Market Size Growth Rate by Purpose of Testing, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Pregnancy and Ovulation Testing Market Size Growth Rate by Biomarker, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Pregnancy and Ovulation Testing Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Pregnancy and Ovulation Testing Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Pregnancy and Ovulation Testing Revenue by Region (US$ Million), 2021-2026
Table 7. Global Pregnancy and Ovulation Testing Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Pregnancy and Ovulation Testing Revenue by Players (US$ Million), 2021-2026
Table 10. Global Pregnancy and Ovulation Testing Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Pregnancy and Ovulation Testing Revenue, 2025
Table 13. Global Pregnancy and Ovulation Testing Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Pregnancy and Ovulation Testing Companies Headquarters
Table 15. Global Pregnancy and Ovulation Testing Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Pregnancy and Ovulation Testing Revenue by Type (US$ Million), 2021-2026
Table 19. Global Pregnancy and Ovulation Testing Revenue by Type (US$ Million), 2027-2032
Table 20. Global Pregnancy and Ovulation Testing Revenue by Purpose of Testing (US$ Million), 2021-2026
Table 21. Global Pregnancy and Ovulation Testing Revenue by Purpose of Testing (US$ Million), 2027-2032
Table 22. Global Pregnancy and Ovulation Testing Revenue by Biomarker (US$ Million), 2021-2026
Table 23. Global Pregnancy and Ovulation Testing Revenue by Biomarker (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Pregnancy and Ovulation Testing Revenue by Application (US$ Million), 2021-2026
Table 26. Global Pregnancy and Ovulation Testing Revenue by Application (US$ Million), 2027-2032
Table 27. Pregnancy and Ovulation Testing High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Pregnancy and Ovulation Testing Growth Accelerators and Market Barriers
Table 31. North America Pregnancy and Ovulation Testing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Pregnancy and Ovulation Testing Growth Accelerators and Market Barriers
Table 33. Europe Pregnancy and Ovulation Testing Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Pregnancy and Ovulation Testing Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Pregnancy and Ovulation Testing Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Pregnancy and Ovulation Testing Investment Opportunities and Key Challenges
Table 37. Central and South America Pregnancy and Ovulation Testing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Pregnancy and Ovulation Testing Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Pregnancy and Ovulation Testing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. SPD (Clearblue) Corporation Information
Table 41. SPD (Clearblue) Description and Major Businesses
Table 42. SPD (Clearblue) Product Features and Attributes
Table 43. SPD (Clearblue) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. SPD (Clearblue) Revenue Proportion by Product in 2025
Table 45. SPD (Clearblue) Revenue Proportion by Application in 2025
Table 46. SPD (Clearblue) Revenue Proportion by Geographic Area in 2025
Table 47. SPD (Clearblue) Pregnancy and Ovulation Testing SWOT Analysis
Table 48. SPD (Clearblue) Recent Developments
Table 49. First Response Corporation Information
Table 50. First Response Description and Major Businesses
Table 51. First Response Product Features and Attributes
Table 52. First Response Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. First Response Revenue Proportion by Product in 2025
Table 54. First Response Revenue Proportion by Application in 2025
Table 55. First Response Revenue Proportion by Geographic Area in 2025
Table 56. First Response Pregnancy and Ovulation Testing SWOT Analysis
Table 57. First Response Recent Developments
Table 58. Gregory Pharmaceutical (e.p.t) Corporation Information
Table 59. Gregory Pharmaceutical (e.p.t) Description and Major Businesses
Table 60. Gregory Pharmaceutical (e.p.t) Product Features and Attributes
Table 61. Gregory Pharmaceutical (e.p.t) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Gregory Pharmaceutical (e.p.t) Revenue Proportion by Product in 2025
Table 63. Gregory Pharmaceutical (e.p.t) Revenue Proportion by Application in 2025
Table 64. Gregory Pharmaceutical (e.p.t) Revenue Proportion by Geographic Area in 2025
Table 65. Gregory Pharmaceutical (e.p.t) Pregnancy and Ovulation Testing SWOT Analysis
Table 66. Gregory Pharmaceutical (e.p.t) Recent Developments
Table 67. Equinox Biotech Corporation Information
Table 68. Equinox Biotech Description and Major Businesses
Table 69. Equinox Biotech Product Features and Attributes
Table 70. Equinox Biotech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Equinox Biotech Revenue Proportion by Product in 2025
Table 72. Equinox Biotech Revenue Proportion by Application in 2025
Table 73. Equinox Biotech Revenue Proportion by Geographic Area in 2025
Table 74. Equinox Biotech Pregnancy and Ovulation Testing SWOT Analysis
Table 75. Equinox Biotech Recent Developments
Table 76. Wondfo Corporation Information
Table 77. Wondfo Description and Major Businesses
Table 78. Wondfo Product Features and Attributes
Table 79. Wondfo Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Wondfo Revenue Proportion by Product in 2025
Table 81. Wondfo Revenue Proportion by Application in 2025
Table 82. Wondfo Revenue Proportion by Geographic Area in 2025
Table 83. Wondfo Pregnancy and Ovulation Testing SWOT Analysis
Table 84. Wondfo Recent Developments
Table 85. Easy@Home Corporation Information
Table 86. Easy@Home Description and Major Businesses
Table 87. Easy@Home Product Features and Attributes
Table 88. Easy@Home Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Easy@Home Recent Developments
Table 90. BlueCross Corporation Information
Table 91. BlueCross Description and Major Businesses
Table 92. BlueCross Product Features and Attributes
Table 93. BlueCross Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. BlueCross Recent Developments
Table 95. Fairhaven Health Corporation Information
Table 96. Fairhaven Health Description and Major Businesses
Table 97. Fairhaven Health Product Features and Attributes
Table 98. Fairhaven Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Fairhaven Health Recent Developments
Table 100. PRIMA Lab Corporation Information
Table 101. PRIMA Lab Description and Major Businesses
Table 102. PRIMA Lab Product Features and Attributes
Table 103. PRIMA Lab Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. PRIMA Lab Recent Developments
Table 105. Cyclotest Corporation Information
Table 106. Cyclotest Description and Major Businesses
Table 107. Cyclotest Product Features and Attributes
Table 108. Cyclotest Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Cyclotest Recent Developments
Table 110. Rohto Corporation Information
Table 111. Rohto Description and Major Businesses
Table 112. Rohto Product Features and Attributes
Table 113. Rohto Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Rohto Recent Developments
Table 115. Lobeck Medical Corporation Information
Table 116. Lobeck Medical Description and Major Businesses
Table 117. Lobeck Medical Product Features and Attributes
Table 118. Lobeck Medical Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Lobeck Medical Recent Developments
Table 120. QuidelOrtho Corporation Information
Table 121. QuidelOrtho Description and Major Businesses
Table 122. QuidelOrtho Product Features and Attributes
Table 123. QuidelOrtho Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. QuidelOrtho Recent Developments
Table 125. Mankind Consumer Products Corporation Information
Table 126. Mankind Consumer Products Description and Major Businesses
Table 127. Mankind Consumer Products Product Features and Attributes
Table 128. Mankind Consumer Products Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. Mankind Consumer Products Recent Developments
Table 130. Hangzhou Singclean Medical Corporation Information
Table 131. Hangzhou Singclean Medical Description and Major Businesses
Table 132. Hangzhou Singclean Medical Product Features and Attributes
Table 133. Hangzhou Singclean Medical Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Hangzhou Singclean Medical Recent Developments
Table 135. Technologies, Platforms and Infrastructure
Table 136. Distributors List
Table 137. Market Trends and Market Evolution
Table 138. Market Drivers and Opportunities
Table 139. Market Challenges, Risks, and Restraints
Table 140. Research Programs/Design for This Report
Table 141. Key Data Information from Secondary Sources
Table 142. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Pregnancy and Ovulation Testing Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Coloration Test Product Picture
Figure 3. Digital Test Product Picture
Figure 4. Global Pregnancy and Ovulation Testing Market Size Growth Rate by Purpose of Testing, 2021 vs 2025 vs 2032 (US$ Million)
Figure 5. Pregnancy Test Product Picture
Figure 6. Ovulation Test Product Picture
Figure 7. Global Pregnancy and Ovulation Testing Market Size Growth Rate by Biomarker, 2021 vs 2025 vs 2032 (US$ Million)
Figure 8. hCG-Based Test Product Picture
Figure 9. LH-Based Test Product Picture
Figure 10. Multi-Hormone Test Product Picture
Figure 11. Global Pregnancy and Ovulation Testing Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 12. Fertility Centers
Figure 13. Hospitals
Figure 14. Clinics
Figure 15. Others
Figure 16. Pregnancy and Ovulation Testing Report Years Considered
Figure 17. Global Pregnancy and Ovulation Testing Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 18. Global Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 19. Global Pregnancy and Ovulation Testing Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 20. Global Pregnancy and Ovulation Testing Revenue-Based Market Share by Region (2021-2032)
Figure 21. Global Pregnancy and Ovulation Testing Revenue-Based Market Share Ranking (2025)
Figure 22. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 23. Coloration Test Revenue-Based Market Share by Player in 2025
Figure 24. Digital Test Revenue-Based Market Share by Player in 2025
Figure 25. Global Pregnancy and Ovulation Testing Revenue-Based Market Share by Type (2021-2032)
Figure 26. Global Pregnancy and Ovulation Testing Revenue-Based Market Share by Purpose of Testing (2021-2032)
Figure 27. Global Pregnancy and Ovulation Testing Revenue-Based Market Share by Biomarker (2021-2032)
Figure 28. Global Pregnancy and Ovulation Testing Revenue-Based Market Share by Application (2021-2032)
Figure 29. North America Pregnancy and Ovulation Testing Revenue YoY (US$ Million), 2021-2032
Figure 30. North America Top 5 Players Pregnancy and Ovulation Testing Revenue (US$ Million) in 2025
Figure 31. North America Pregnancy and Ovulation Testing Revenue (US$ Million) by Application (2021-2032)
Figure 32. US Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 33. Canada Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 34. Mexico Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 35. Europe Pregnancy and Ovulation Testing Revenue YoY (US$ Million), 2021-2032
Figure 36. Europe Top 5 Players Pregnancy and Ovulation Testing Revenue (US$ Million) in 2025
Figure 37. Europe Pregnancy and Ovulation Testing Revenue (US$ Million) by Application (2021-2032)
Figure 38. Germany Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 39. France Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 40. U.K. Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 41. Italy Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 42. Russia Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 43. Asia-Pacific Pregnancy and Ovulation Testing Revenue YoY (US$ Million), 2021-2032
Figure 44. Asia-Pacific Top 8 Players Pregnancy and Ovulation Testing Revenue (US$ Million) in 2025
Figure 45. Asia-Pacific Pregnancy and Ovulation Testing Revenue (US$ Million) by Application (2021-2032)
Figure 46. Indonesia Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 47. Japan Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 48. South Korea Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 49. Australia Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 50. India Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 51. Indonesia Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 52. Vietnam Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 53. Malaysia Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 54. Philippines Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 55. Singapore Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 56. Central and South America Pregnancy and Ovulation Testing Revenue YoY (US$ Million), 2021-2032
Figure 57. Central and South America Top 5 Players Pregnancy and Ovulation Testing Revenue (US$ Million) in 2025
Figure 58. Central and South America Pregnancy and Ovulation Testing Revenue (US$ Million) by Application (2021-2032)
Figure 59. Brazil Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 60. Argentina Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 61. Middle East and Africa Pregnancy and Ovulation Testing Revenue YoY (US$ Million), 2021-2032
Figure 62. Middle East and Africa Top 5 Players Pregnancy and Ovulation Testing Revenue (US$ Million) in 2025
Figure 63. Middle East and Africa Pregnancy and Ovulation Testing Revenue (US$ Million) by Application (2021-2032)
Figure 64. GCC Countries Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 65. Israel Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 66. Egypt Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 67. South Africa Pregnancy and Ovulation Testing Revenue (US$ Million), 2021-2032
Figure 68. Pregnancy and Ovulation Testing Value Chain Mapping
Figure 69. Channels of Distribution (Direct Vs Distribution)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed